<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1280">
  <stage>Registered</stage>
  <submitdate>15/05/2006</submitdate>
  <approvaldate>29/05/2006</approvaldate>
  <actrnumber>ACTRN12606000200583</actrnumber>
  <trial_identification>
    <studytitle>Effect of Rosiglitazone on Glucocorticoid-stimulated 11betaHSD-1 Activity in Skeletal Muscle</studytitle>
    <scientifictitle>Does Rosiglitazone Inhibit Glucocorticoid-stimulated 11betaHSD-1 Activity in Skeletal Muscle of Subjects with Type 2 diabetes?</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Type 2 diabetes</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Rosiglitazone 8mg per day orally for 24 days.
Dexamethasone 4mg per day for 4 days orally, commencing on Day 18 of the Rosiglitazone treatment</interventions>
    <comparator>Rosiglitazone 8mg per day orally for 24 days without additional treatment.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Skeletal muscle 11betaHSD-1 activity.  Skeletal muscle 11betaHSD-1 activity refers to the activity of an enzyme which converts the inactive steroid cortisone to the active steroid cortisol. We are studying this enzyme in muscle. It is also found in liver and adipose tissue.</outcome>
      <timepoint>Measured at day 0 and 22.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Skeletal muscle 11betaHSD-1 mRNA </outcome>
      <timepoint>Day 0 vs Day 22</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Skeletal muscle hexose 6 phosphate dehydrogenase mRNA </outcome>
      <timepoint>Day 0 vs Day 22</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Insulin sensitivity as measured by iv glucose tolerance test</outcome>
      <timepoint>Day 0 vs Day 22</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Self monitored blood glucose recordings</outcome>
      <timepoint>During  the 4 days of dexamethasone treatment</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Type 2 diabetes mellitus by current WHO criteriaTreated with diet alone, metformin, sulphonylureas and/or acarboseGood understanding of written and spoken English</inclusivecriteria>
    <inclusiveminage>30</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Treatment with insulin or thiazolidinedionesSignificant chronic renal impairment, estimated glomerular filtration rate (eGFR) &lt;40ml/min and/or serum creatinine &gt;200umol/LLiver disease as defined by alanine transaminase (ALT) &gt;2x upper limit of laboratory normal rangeUncontrolled diabetes as defined by Haemoglobin A1c (HbA1c) &gt;10%Unstable heart disease as defined by myocardial infarction within 3 months, class III/IV angina pectoris or congestive heart failure.Active infection of any kind.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Sealed opaque envelopes</concealment>
    <sequence>via computer</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/08/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr Warrick Inder</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Glaxo Smith Kline</fundingname>
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Dr Christina Jang</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>Glaxo Smith Kline</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The study will investigate whether pretreatment with the drug Rosiglitazone attenuates the increase in activity of muscle 11betaHSD-1 following treatment with the potent steroid dexamethasone. Dexamethasone is well known to cause an increase in blood glucose levels in people with type 2 diabetes and we are investigating a possible mechanism for this.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Christina Jang</name>
      <address>Department of Endocrinology
St Vincent's Hospital
41 Victoria Parade
Fitzroy VIC 3065</address>
      <phone>+61 3 92883574</phone>
      <fax>+61 3 92883590</fax>
      <email>christina.jang@svhm.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Warrick Inder</name>
      <address>Department of Endocrinology
St Vincent's Hospital
41 Victoria Parade
Fitzroy VIC 3065</address>
      <phone>+61 3 92882211</phone>
      <fax>+61 3 92882581</fax>
      <email>winder@medstv.unimelb.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>